PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

A type of allergy medicine might help treat lung cancer, research suggests

A type of allergy medicine might help treat lung cancer, research suggests
2023-12-06
(Press-News.org) New York, NY (December 6, 2023)—Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).  

And in an early parallel study in humans, combining immunotherapy with dupilumab—an Interleukin-4 (IL-4) receptor-blocking antibody widely used for treating allergies and asthma—boosted patients' immune systems, with one out of the six experiencing significant tumor reduction.  

The findings were described in the December 6 issue of Nature [DOI: 10.1038/s41586-023-06797-9].

“Immunotherapy using checkpoint blockade has revolutionized treatment for non-small cell lung cancer, the most common form of lung cancer, but currently only about a third of patients respond to it alone, and in most patients, the benefit is temporary,” says senior study author Miriam Merad, MD, PhD, Director of the Marc and Jennifer Lipschultz Precision Immunology Institute and Chair of the Department of Immunology and Immunotherapy at the Icahn School of Medicine at Mount Sinai. “A big focus of our program TARGET is to use single cell technology and artificial intelligence to identify molecular immune programs that can dampen tumor immune response to checkpoint blockade.”

Also known as a PD1 inhibitor, checkpoint blockade is a type of cancer immunotherapy that can unleash the cancer-killing activity of T cells.

“Using single cell technologies, we discovered that the immune cells infiltrating lung cancers, as well as other cancers we studied, exhibited characteristics of a 'type 2' immune response, which is commonly associated with allergic conditions like eczema and asthma,” says first study author Nelson LaMarche, PhD, a postdoctoral research fellow in the lab of Dr. Merad.

“These results led us to explore whether we could repurpose a medication typically used for allergic conditions to ‘rescue’ or enhance tumor response to checkpoint blockade,” says Thomas Marron, MD, PhD, Director of the Early Phase Trial Unit at Mount Sinai’s Tisch Cancer Center, and co-senior author of the study. “Strikingly, we found that IL-4 blockade enhanced lung cancer response to checkpoint blockade in mice and in six lung cancer patients with treatment-resistant disease. In fact, one patient whose lung cancer was growing despite checkpoint blockade had nearly all their cancer disappear after receiving just three doses of the allergy medication, and his cancer remains controlled today, over 17 months later."

The researchers are encouraged by the initial results but emphasize the need for larger clinical trials to validate the drug's efficacy in treating NSCLC. Beyond the clinical trial findings reported in the current Nature paper, the investigators have now expanded the clinical trial, adding dupilumab to checkpoint blockade for a larger group of lung cancer patients, and Dr. Marron recently received a grant from the Cancer Research Institute to study the effects in early-stage lung cancer as well. Through these trials, they are searching for biomarkers that can predict which cancer patients might benefit from dupilumab treatment and which may not.

“In our relentless pursuit of progress, the Cancer Research Institute (CRI) proudly supports the visionary team at the Icahn School of Medicine at Mount Sinai. Their findings validate our commitment to funding research across the entire discovery continuum, from the lab to clinical implementation, driven by cutting-edge technology and data. We're eager to witness our support delivering new hope by uncovering pathways to enhance checkpoint blockade responses. We champion this discovery and take pride in being part of its journey from lab to clinic, reinforcing our commitment to transforming lives,” says Jill O’Donnell-Tormey, PhD, CEO and director of scientific affairs at CRI.

The paper is titled “An IL-4 signaling axis in bone marrow drives pro-tumorigenic myelopoiesis.” Please see the Nature paper to view competing interests [DOI: 10.1038/s41586-023-06797-9].

The remaining authors, all with Icahn Mount Sinai except where indicated, are Samarth Hegde, PhD; Matthew D. Park, MD/PhD candidate; Barbara B. Maier, PhD, Icahn Mount Sinai and Austrian Academy of Sciences, Vienna; Leanna Troncoso; Jessica Le Berichel; Pauline Hamon, PhD, Meriem Belabed, PhD; Raphaël Mattiuz, PhD; Clotilde Hennequin; Theodore Chin; Amanda M. Reid; Iván Reyes-Torres, PhD; Erika Nemeth, MD, PhD candidate; Ruiyuan Zhang (Columbia University); Oakley C. Olson, PhD (Columbia University); Deborah B. Doroshow, MD, PhD;  Nicholas C. Rohs, MD; Jorge E. Gomez, MD; Rajwanth Veluswamy, MD, MSCR; Nicole Hall; Nicholas Venturini, MD/PhD candidate; Florent Ginhoux, PhD (Agency for Science, Technology and Research, Singapore; Gustave Roussy Cancer Campus, France; Shanghai Jiao Tong University School of Medicine, China; and SingHealth Duke-NUS Translational Immunology Institute, Singapore); Zhaoyuan Liu, PhD (Shanghai Jiao Tong University School of Medicine, China); Mark Buckup, MD/PhD candidate; Igor Figueiredo; Vladimir Roudko, PhD; Kensuke Miyake, PhD (Tokyo Medical and Dental University, Japan); Hajime Karasuyama (Tokyo Medical and Dental University, Japan); Edgar Gonzalez-Kozlova, PhD; Sacha Gnjatic, PhD; Emmanuelle Passegué, PhD (Columbia University); Seunghee Kim-Schulze, PhD, Brian D. Brown, PhD; Fred R. Hirsch MD, PhD; Brian S. Kim, MD, MTR, FAAD; and Thomas U. Marron, MD, PhD.

The study was funded by National Institutes of Health grants CA257195, CA254104, CA154947, CA224319, DK124165, CA263705, CA196521, K00 CA223043, U01CA282114, and Cancer Research Institute grants CRI3931 and CRI3617, as well as by a Bristol Myers Squibb Irvington Research Fellowship (CRI3931) and a 2021 AACR-AstraZeneca Immuno-oncology Research Fellowship (21-40-12-MATT).

-####-

About the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight- member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.  

Ranked 14th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 44 academic departments and 36 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases. 

Icahn Mount Sinai offers highly competitive MD, PhD, and Master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the Health System. In addition, more than 550 postdoctoral research fellows are in training within the Health System. 

A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into healthcare products and services that benefit the public.

Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs.

Through the Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.

The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.

------------------------------------------------------- 

* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.

 

 

END


[Attachments] See images for this press release:
A type of allergy medicine might help treat lung cancer, research suggests A type of allergy medicine might help treat lung cancer, research suggests 2 A type of allergy medicine might help treat lung cancer, research suggests 3

ELSE PRESS RELEASES FROM THIS DATE:

Economic burden of health conditions associated with adverse childhood experiences among US adults

2023-12-06
About The Study: In this cross-sectional analysis of the U.S. adult population, 63% of adults had adverse childhood experiences (ACEs). The economic burden of ACE-related health conditions was substantial. The findings suggest that measuring the economic burden of ACEs can support decision-making about investing in strategies to improve population health.  Authors: Cora Peterson, Ph.D., of the Centers for Disease Control and Prevention in Atlanta, is the corresponding author.   To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamanetworkopen.2023.46323) Editor’s Note: Please ...

Evaluation of stigma toward individuals with acne

2023-12-06
About The Study: This survey study with 1,357 respondents demonstrates that stigmatizing attitudes toward patients with acne existed across a variety of social and professional scenarios, with severe acne and acne in darker skin tone being associated with a greater degree of stigma. These findings highlight the need to identify approaches to reduce stigmatizing attitudes in the community and for adequate access to care, which might prevent negative downstream effects related to these stigmatizing attitudes. Authors: John ...

COVID-19 rapid antigen tests with self-collected vs health care worker–collected nasal and throat swab specimens

2023-12-06
About The Study: This randomized clinical trial found that a single health care worker-collected throat specimen had higher sensitivity for rapid antigen testing for SARS-CoV-2 than a nasal specimen. In contrast, the self-collected nasal specimens had higher sensitivity than throat specimens for symptomatic participants. Adding a throat specimen to the standard practice of collecting a single nasal specimen could improve sensitivity for rapid antigen testing in health care and home-based settings.  Authors: Tobias Todsen, M.D., Ph.D., of Copenhagen University Hospital in ...

First map of human limb development reveals unexpected growth processes and explains syndromes found at birth

First map of human limb development reveals unexpected growth processes and explains syndromes found at birth
2023-12-06
Human fingers and toes do not grow outward; instead, they form from within a larger foundational bud, as intervening cells recede to reveal the digits beneath. This is among many processes captured for the first time as scientists unveil a spatial cell atlas of the entire developing human limb, resolved in space and time. Researchers at the Wellcome Sanger Institute, Sun Yat-sen University, EMBL’s European Bioinformatics Institute and collaborators applied cutting-edge single-cell and spatial technologies to create an atlas characterising the cellular landscape of the early human limb, pinpointing the exact ...

Stanford Medicine-led study finds way to predict which of our organs will fail first

2023-12-06
Like any typical car or house or society, the pace at which parts of our bodies fall apart varies from part to part.  A study of 5,678 people, led by Stanford Medicine investigators, has shown that our organs age at different rates — and when an organ’s age is especially advanced in comparison with its counterpart in other people of the same age, the person carrying it is at heightened risk both for diseases associated with that organ and for dying. According to the study, about 1 in every 5 reasonably ...

Bowtie resonators that build themselves bridge the gap between nanoscopic and macroscopic

Bowtie resonators that build themselves bridge the gap between nanoscopic and macroscopic
2023-12-06
A central goal in quantum optics and photonics is to increase the strength of the interaction between light and matter to produce, e.g., better photodetectors or quantum light sources. The best way to do that is to use optical resonators that store light for a long time, making it interact more strongly with matter. If the resonator is also very small, such that light is squeezed into a tiny region of space, the interaction is enhanced even further. The ideal resonator would store light for a long time in a region at the size of a single atom. Physicists and engineers have struggled for decades with how ...

Embargoed press release: Blood hormone levels key to identifying which post-menopausal women will benefit most from taking anastrozole to prevent breast cancer 

2023-12-06
Research led by Queen Mary University of London’s Wolfson Institute of Population Health has found that hormone levels, measured through blood tests, are an important indicator of whether women will benefit from recently licensed medication for the prevention of breast cancer.    Aromatase inhibitors such as anastrozole are recommended by the National Institute of Clinical Care and Excellence (NICE) as an option for preventive therapy in post-menopausal women at high risk of breast cancer. Anastrozole (Arimidex) is now also licensed by the ...

MD Anderson Research Highlights: ASH 2023 Special Edition

2023-12-06
ABSTRACTS: 162, 309, 322, 364, 741, 774, 856, 983 SAN DIEGO ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This special edition features oral presentations from the 2023 American Society of Hematology (ASH) Annual Meeting, describing the latest scientific and clinical breakthroughs for hematological cancers. In addition to these ...

EHR-based public health surveillance for chronic diseases

2023-12-06
INDIANAPOLIS – As hospitalizations due to chronic conditions increase across the United States, attention is focusing on using data collected in electronic health records (EHRs) by healthcare systems to enable public health departments to gain understanding of the incidence and prevalence of hypertension, diabetes, asthma, obesity and other chronic diseases with the ultimate goal of improving disease outcomes. In the U.S., 90 percent of clinicians, medical laboratories, imaging centers and other providers use EHR systems, providing ample data on individuals with access to healthcare. However, access ...

Tucatinib plus trastuzumab emtansine may benefit patients with advanced or metastatic HER2-positive breast cancer

2023-12-06
SAN ANTONIO – A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023. T-DM1 is an antibody-drug conjugate comprised of trastuzumab (Herceptin) and the cytotoxic drug emtansine. It was approved for use ...

LAST 30 PRESS RELEASES:

Oceanic life found to be thriving thanks to Saharan dust blown from thousands of kilometers away

Analysis sheds light on COVID-19-associated disease in Japan

Cooler heads prevail: New research reveals best way to prevent dogs from overheating

UC Riverside medical school develops new curriculum to address substance use crisis

Food fussiness a largely genetic trait from toddlerhood to adolescence

Celebrating a century of scholarship: Isis examines the HSS at 100

Key biomarkers identified for predicting disability progression in multiple sclerosis

Study: AI could lead to inconsistent outcomes in home surveillance

Study: Networks of Beliefs theory integrates internal & external dynamics

Vegans’ intake of protein and essential amino acids is adequate but ultra-processed products are also needed

Major $21 million Australian philanthropic investment to bring future science into disease diagnosis

Innovating alloy production: A single step from ores to sustainable metals

New combination treatment brings hope to patients with advanced bladder cancer

Grants for $3.5M from TARCC fund new Alzheimer’s disease research at UTHealth Houston

UTIA researchers win grant for automation technology for nursery industry

Can captive tigers be part of the effort to save wild populations?

The Ocean Corporation collaborates with UTHealth Houston on Space Medicine Fellowship program

Mysteries of the bizarre ‘pseudogap’ in quantum physics finally untangled

Study: Proteins in tooth enamel offer window into human wellness

New cancer cachexia treatment boosts weight gain and patient activity

Rensselaer researcher receives $3 million grant to explore gut health

Elam named as a Fellow of the Electrochemical Society

Study reveals gaps in access to long-term contraceptive supplies

Shining a light on the roots of plant “intelligence”

Scientists identify a unique combination of bacterial strains that could treat antibiotic-resistant gut infections

Pushing kidney-stone fragments reduces stones’ recurrence

Sweet success: genomic insights into the wax apple's flavor and fertility

New study charts how Earth’s global temperature has drastically changed over the past 485 million years, driven by carbon dioxide

Scientists say we have enough evidence to agree global action on microplastics

485 million-year temperature record of Earth reveals Phanerozoic climate variability

[Press-News.org] A type of allergy medicine might help treat lung cancer, research suggests